U.S. markets closed

Needham: Peloton is a key beneficiary of COVID-19

On Friday, Needham analysts reiterated their buy rating — and $50 price target — on shares of Peloton following comments by the company’s CFO, Jill Woodworth. The firm’s argument was that Peloton has been a key beneficiary of COVID-19 and will continue to do so. The Final Round panel discusses.